Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PS433540 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Irbesartan 300mg | ACTIVE_COMPARATOR | Irbesartan 300 mg once daily |
| Placebo | PLACEBO_COMPARATOR | Blinded Placebo Treatment |
| PS433540 200mg | EXPERIMENTAL | PS433540 200mg once daily |
| PS433540 400mg | EXPERIMENTAL | PS433540 400mg once daily |
| PS433540 800mg | EXPERIMENTAL | PS433540 800mg once daily |
| 1 | PLACEBO_COMPARATOR | Matching Placebo |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| irbesartan | DRUG | 300 mg (2 x 150 mg capsules) once daily for 12 weeks |
| placebo | DRUG | placebo capsules once daily for 12 weeks |
| PS433540 | DRUG | 200 mg (2 x 100 mg capsules) once daily for 12 weeks |
Inclusion Criteria: * Males or females 18 - 70 years * Mean seated Systolic Blood Pressure (SBP) ≥ 140 mmHg and \< 180 mmHg and mean seated Diastolic Blood Pressure (DBP) \> 90 and \< 109 mmHg at two consecutive qualifying visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the tw...
PS433540 is an investigational small molecule being developed for the treatment of hypertension, a cardiovascular condition. It is currently in Phase 2 clinical development and has not been approved by the FDA. Two Phase 2 trials have been completed to evaluate its safety and efficacy in patients with hypertension.
PS433540 is being developed by Ligand Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol LGND. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating hypertension.
PS433540 is in Phase 2 clinical development. Two Phase 2 trials have been completed, both focusing on the treatment of hypertension. The drug is still investigational and has not received FDA approval. Its safety and efficacy are being evaluated in clinical studies.
PS433540 has been studied in two completed Phase 2 clinical trials: NCT00522925, which enrolled 280 participants with hypertension in the United States, and NCT00635232, which enrolled 261 participants. Both trials were randomized, double-blind, and placebo-controlled, with a combined enrollment of 541 participants.
PS433540 is the primary name used in clinical trials for this investigational hypertension treatment. No alternative names have been reported in the available clinical trial data. The drug is being developed by Ligand Pharmaceuticals and is currently in Phase 2 development.